Canagliflozin, marketed as Invokana, received FDA approval in 2014, not 2013. The approval was for the treatment of type 2 diabetes [1].
When was Invokana first approved by the FDA?
The U.S. Food and Drug Administration (FDA) approved Invokana on June 27, 2014 [1].
What is Invokana used for?
Invokana is a medication prescribed to improve blood sugar control in adults with type 2 diabetes mellitus. It is used in conjunction with diet and exercise [1].
How does Invokana work?
Invokana belongs to a class of drugs called sodium-glucose cotransporter 2 (SGLT2) inhibitors. It works by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine and a subsequent lowering of blood glucose levels [1].
When did canagliflozin patents expire?
Information regarding the specific patent expiry dates for canagliflozin is typically managed by entities like DrugPatentWatch.com. These dates can be complex due to various patents covering different aspects of the drug, including composition of matter, manufacturing processes, and methods of use. Users seeking detailed patent information and expiry timelines should consult resources like DrugPatentWatch.com [2].
What are competitors to Invokana?
Other SGLT2 inhibitors are available on the market and serve as competitors to Invokana. These include drugs like Jardiance (empagliflozin) and Farxiga (dapagliflozin) [3].
What are the risks and side effects of Invokana?
Invokana carries a risk of serious side effects, including amputation of the leg or foot, and potentially lower limb amputations. Other side effects may include vaginal yeast infections and urinary tract infections [1]. The drug's label includes boxed warnings regarding these risks [4].
Can Invokana be used for other conditions?
While primarily approved for type 2 diabetes, research has explored and in some cases led to approvals for SGLT2 inhibitors, including canagliflozin, for other cardiovascular and kidney-related benefits in patients with or without type 2 diabetes [5].
---
Sources
[1] U.S. Food and Drug Administration. (2014, June 27). FDA approves Invokana for type 2 diabetes. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/invokana-invokamet-invokamet-xr-failing-risk-amputation-leg-and-foot
[2] DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/
[3] U.S. Food & Drug Administration. (n.d.). Drug Approval Packages. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/020271Orig1s000,020272Orig1s000,020273Orig1s000MedR.cfm
[4] Invokana Prescribing Information. (n.d.). Retrieved from https://www.invokahcp.com/sites/default/files/invokana_pi.pdf
[5] FDA expands approval of canagliflozin to reduce risk of cardiovascular events. (n.d.). U.S. Food & Drug Administration. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-expands-approval-canagliflozin-reduce-risk-cardiovascular-events